2025 · 1st Quarter (Jan 1 - Mar 31)

THE CAMPAIGN FOR SUSTAINABLE RX PRICING

Filed by MEHLMAN CONSULTING, INC..

Open official filing

Source-reported fields

Filing overview

Type: 1st Quarter - Report
Posted: Apr 17, 2025
Income: $90,000.00
Expenses: Not reported
Registrant: MEHLMAN CONSULTING, INC.
Client: THE CAMPAIGN FOR SUSTAINABLE RX PRICING
Filing UUID: 01e04265-4c25-42a7-890b-286c000310a7
Termination date: Not reported

Literal source text

Lobbying issues and bill citations

MMM · Medicare/Medicaid

Prescription drug pricing issues. S. 229 Drug-price Transparency for Consumers (DTC) Act.

Literal federal measure citations: S. 229

PHA · Pharmacy

Prescription drug pricing issues. H.R. 1843/S. 1302 - Increasing Transparency in Generic Drug Applications Act.

Literal federal measure citations: H.R. 1843, S. 1302

CPT · Copyright/Patent/Trademark

Patent abuse issues. S.1040 - Drug Competition Enhancement Act. S.1041 - Affordable Prescriptions for Patients Act. S.1096 - Preserve Access to Affordable Generics and Biosimilars Act. S.1095 - Stop STALLING Act. S. 1097 - Interagency Patent Coordination and Improvement Act of 2025. S. 43 - Skinny Labels, Big Savings Act.

Literal federal measure citations: S.1040, S.1041, S.1096, S.1095, S. 1097, S. 43

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.